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Abstract
We examined transforming growth factor (TGF) K, epidermal growth factor (EGF) and EGF receptor (EGFR) expression
and signaling in three drug resistant MCF-7 human breast cancer sublines and asked whether these pathways contribute to
the drug resistance phenotype. In the resistant sublines, upregulation of both TGFK and EGFR mRNA was observed. In an
apparent contrast with upregulated growth factor and receptor gene expression, the drug resistant sublines displayed a
reduced growth rate. Defects in the EGFR signaling pathway cascade were found in all examined drug resistant sublines,
including altered EGF-induced Shc, Raf-1, or mitogen-activated protein kinase phosphorylation. Induction of c-fos mRNA
expression by EGF was impaired in the sublines compared to parental MCF-7 cells. In contrast, the induction of the stress-
activated protein kinase activity was similar in both parental and drug resistant cells. Evaluating the link between the reduced
growth rate and drug resistance, serum starvation experiments were performed. These studies demonstrated that a reduced
proliferative activity resulted in a marked reduction in sensitivity to cytotoxic agents in the parental MCF-7 cells. We propose
that the altered EGFR levels frequently observed in drug resistant breast cancer cells are associated with perturbations in the
signaling pathway that mediate a reduced proliferative rate and thereby contribute to drug resistance. ß 2000 Elsevier
Science B.V. All rights reserved.
1. Introduction
Drug resistance is one of the major obstacles to
the eradication of cancer with chemotherapy. While
drug resistance is often mediated by speci¢c mecha-
nisms, through altered drug uptake, e¥ux, metabo-
lism or target, it is increasingly recognized that other
components of cell biology may also play a role.
Several lines of evidence link phenotypic alterations
to drug resistance. In transfection studies, it has been
shown that overexpression of epidermal growth fac-
tor (EGF) receptor or c-erbB2 in breast cancer cells
leads to an increase in cellular resistance to chemo-
therapeutic drugs [5,16,56].
Conversely, cells that have been selected for multi-
drug resistance express a wide variety of phenotypic
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alterations. In a survey of 15 drug resistant human
breast cancer sublines, we noted frequent upregula-
tion of transforming growth factor (TGF) K, amphi-
regulin (AR), EGF receptor (EGFR), c-erbB2, c-
erbB3 and insulin-like growth factor-I receptor ex-
pression [55]. Other reported observations have in-
cluded protein kinase C overexpression, increased vi-
mentin expression, increased accumulation of p53
protein, and altered expression of hormone or
growth factor receptors [6,23,27,32,50,51]. Decreased
levels of estrogen receptor have been noted in drug
resistant human breast cancer sublines accompanying
increased levels of EGFR and TGFK [15,55]. In clin-
ical breast cancer, this phenotype has been associated
with a poor patient prognosis and the failure of hor-
monal therapy [11,37,45].
TGFK, EGF and AR are ligands of the EGFR
[38]. They are produced in some human breast cancer
cells and may participate in the malignant process in
an autocrine manner. Binding of a ligand to the
EGFR at the cell surface results in activation of
the tyrosine kinase of the intracellular domain of
the receptor. Activation of the tyrosine kinase ini-
tiates a cascade of events, including receptor auto-
phosphorylation and subsequent phosphorylation of
other substrates [47]. The autophosphorylated recep-
tor tyrosine residues present speci¢c binding sites for
intracellular proteins harboring SH2 domains such as
Shc, thereby recruiting them and proteins complexed
with them to the inner surface of the cell membrane.
Ras is activated, leading to the successive phosphor-
ylation and activation of multiple protein kinases
including Raf-1, mitogen-activated protein kinase
(MAPK) kinase and MAPK. MAPK phosphorylates
multiple cytoplasmic substrates, and translocates to
the nucleus, where it ultimately leads to altered gene
expression and increased growth rate [54].
It is not clear whether or how these signaling
events might be linked to drug resistance. In the
present study, earlier observations of upregulated
EGFR expression were extended by evaluating the
role of proliferative activity and EGFR signaling
pathway components in the drug resistance of multi-
ple MCF-7 resistant sublines. We found slower
growth rates coupled with abnormalities in the
EGFR signaling pathway, and a di¡erential e¡ect
of reduced proliferative activity on the sensitivity to
cytotoxic agents. We hypothesize that in these breast
cancer sublines, a reduced proliferative rate, medi-
ated by aberrations in growth factor signaling, con-
tributes to the drug resistant phenotype.
2. Materials and methods
2.1. Cell culture methods
All cells were grown as monolayer cultures at 37‡C
with 5% CO2 and maintained by regular passage in
improved minimum essential Eagle’s medium
(IMEM) supplemented with 10% fetal calf serum
(FCS), 2 mM glutamine, 15 mM HEPES and 25
Wg/ml gentamicin. The MCF-7 AdVp cells were se-
lected in doxorubicin and verapamil (5 Wg/ml) in or-
der to prevent emergence of P-glycoprotein [34]. The
remaining resistant sublines were generated by step-
wise increases in the concentration of the selecting
agent. The sublines were maintained in the concen-
trations of drug described in Table 1. Cells were
consistently cultured for 5^7 days out of drug before
the start of the experiments. In all experiments where
cells were stimulated with EGF, cells were grown
under serum-free conditions for 24^48 h prior to
the addition of EGF in phenol red-free IMEM sup-
plemented with 1 mg/ml bovine serum albumin,
15 mM HEPES, 2 mM glutamine, 5 Wg/ml insulin,
5 Wg/ml transferrin, 5 ng/ml selenium (Sigma, MO,
USA) and 25 Wg/ml gentamicin.
2.2. Cytotoxicity assay and growth curve experiments
Cytotoxicity studies were performed in 96 well
plates in the presence of increasing concentrations
of the cytotoxic compound in IMEM+10% FCS or
0.2% FCS where indicated. Between 2000 and 8000
cells/well were plated and treated 24 h later. After
4 days in culture, the cells were ¢xed in 10% trichloro-
acetic acid and then stained with 0.4% sulforhod-
amine B (Sigma, MO, USA) in 1% acetic acid [49].
The bound dye was solubilized in 200 Wl of 10 mM
unbu¡ered Tris solution and the optical density (OD)
was determined at a wavelength of 540 nm in an
enzyme-linked immunosorbent assay microplate
reader (Bio-Rad Lab. Inc., CA, USA) in quadrupli-
cates. Untreated control wells were assigned a value
of 100% and the IC50 was de¢ned as the dose re-
BBAMCR 14648 5-7-00
K. Wosikowski et al. / Biochimica et Biophysica Acta 1497 (2000) 215^226216
quired to inhibit the OD measured at 540 nm to 50%
of the control value. Results are representative of 2^3
separate experiments. The growth curve experiments
were performed in similar conditions. Sixteen hours
and 3, 5 and 7 days after plating, cells were ¢xed and
analyzed as described above. A growth curve was
generated and from there the doubling time calcu-
lated.
2.3. Riboprobes used in RNA analysis
The 141 bp fragment of EGFR, 603 bp fragment
of TGFK and 220 bp fragment of 36B4 were de-
scribed previously [15] and used to generate radio-
labeled antisense riboprobes for the RNase protec-
tion experiments. A 289 bp SphI^StyI fragment of
EGF, subcloned in pGEM 3, was used to detect
EGFR mRNA, respectively [4]. A 1.4 kb cDNA con-
taining sequences from the middle third of MDR-1
subcloned in a pGEM vector was used for riboprobe
synthesis and Northern blot analysis of the MDR-1
message [55].
2.4. RNA extraction, Northern analysis, RNase
protection assay and reverse transcription
(RT)-PCR
Total RNA was extracted from cells by homoge-
nizing in guanidine isothiocyanate bu¡er followed by
centrifugation over a CsCl cushion.
For Northern analysis, 8 Wg of total RNA was
electrophoretically separated in a 1% agarose, 6%
formaldehyde gel and transferred onto a nylon mem-
brane (Gene Screen Plus, DuPont, NEN, MA,
USA). Equal loading, blotting and quality of RNA
samples were veri¢ed by staining the membrane with
methylene blue. Subsequently, the blots were hybrid-
ized with 32P-labeled MDR-1 riboprobe and exposed
to a ¢lm.
For RNase protection assays, 30 or 60 Wg of total
RNA was hybridized with 3U105 cpm labeled ribo-
probe and then digested for 30 min at 25‡C with 40
Wg/ml RNase A and 28 Wg/ml RNase T1. Following
extraction, samples were separated on a 6% polyac-
rylamide gel and autoradiography was performed.
32P-Labeled riboprobes were prepared according to
the manufacturer’s directions by SP6 or T7 polymer-
ase transcription (Promega, WI, USA) as appropri-
ate for each probe in the presence of [K-32P]uridine
5P-triphosphate (speci¢c activity, 3000 Ci/mmol)
(DuPont, NEN, MA, USA). The intensity of the
autoradiographic signals was determined with a Fo-
toeclipse densitometer (Fotodyne Inc., MI, USA)
and normalized to the 36B4 control gene. The
36B4 gene has been utilized as a control by investi-
gators in studies of mRNA regulation in breast can-
cer cells since its expression is not a¡ected by estro-
gen or other mitogens [44].
Determination of the expression level of MDR-1
by RT-PCR was performed as previously described
using a serial dilution methodology and normalizing
to the level of 28S mRNA in an ethidium-stained gel
[25].
2.5. Immunoprecipitation and immunoblot analysis
Cells were plated in 100 mm petri dishes and se-
rum-starved in serum-free medium for 24^48 h for
reproducible results. Control cells and EGF-stimu-
lated (5^30 min, as indicated) cells were lysed in
TNESV (50 mM Tris, pH = 7.6, 1% NP-40, 2 mM
EDTA, 100 mM NaCl, 1 mM vanadate) with 20 Wg/ml
aprotinin, 20 Wg/ml leupeptin and 1 WM phenylme-
thylsulfonyl£uoride and centrifuged for 30 min at
4‡C at 14 000 rpm in an Eppendorf centrifuge. For
analysis of total protein, 70^80 Wg protein extracts
were fractionated by sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE), trans-
ferred to Immobilon (Millipore, MA, USA) and
probed with the primary antibodies to detect total
EGFR (Ab-5, Calbiochem, La Jolla, CA, USA);
phosphorylated EGFR (pY1173 anti-phospho-
EGFR, mouse monoclonal antibody; Upstate Bio-
technology Inc., Lake Placid, NY, USA); phospho-
tyrosine (clone 4G10, Upstate Biotechnology Inc.,
NY, USA), Raf-1 (C20, Santa Cruz Biotech., CA,
USA) and MAPK (Erk2, Upstate Biotechnology
Inc.) [46]. Horseradish peroxidase-labeled secondary
(Amersham, IL, USA) antibody and light emitting
non-radioactive enhanced chemiluminescence (Re-
naissance, DuPont, NEN, MA, USA) followed by
exposure to an autoradiographic ¢lm was used to
visualize the proteins.
The immunoprecipitation of Shc was carried out
with 750 Wg protein extract, 5 Wg Shc polyclonal anti-
body (Upstate Biotechnology Inc., NY, USA) and 70
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Wl 50% protein A Sepharose (Pharmacia LKB Bio-
tech., NJ, USA). One mg of protein extract, 5 Wg
MAb 528 monoclonal EGFR antibody [20] and 70
Wl 50% protein A:protein G (1:1) Sepharose (Phar-
macia LKB Biotech., NJ, USA) were used to immu-
noprecipitate the EGFR. Immunoprecipitates were
analyzed by Western blotting using monoclonal
anti-phosphotyrosine antibodies (RC20H, Transduc-
tion Lab., KY, USA, and Upstate Biotech. Inc., NY,
USA). The proteins were visualized by chemilumi-
nescence as described above.
2.6. SAPK immunoblot and activity assay
For analysis of SAPK, cells were treated for 1 h
with 1 Wg/ml anisomycin in normal tissue culture
conditions (presence of 10% FCS) and then lysed in
bu¡er containing 25 mM HEPES, pH 7.5, 0.3 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM di-
thiothreitol, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 20 mM L-glycerophosphate,
1 mM sodium vanadate, 4 Wg/ml Pefabloc and 20
Wg/ml leupeptin. Proteins were separated by 10%
SDS^PAGE, transferred as described above and
probed with polyclonal anti-SAPK antibody (C-17,
Santa Cruz Biotech., CA, USA). Chemiluminescence
was used to visualize the proteins as described.
SAPK activity was measured as previously de-
scribed [10]. Brie£y, cells were treated and lysed as
indicated above. SAPK was immunoprecipitated
from 1 mg protein extract with 1 Wg of anti-SAPK
antibody (C-17, Santa Cruz Biotech., CA, USA) and
incubated for 1^2 h and recovered by 1^2 h further
incubation with 20 Wl protein A/G agarose (Santa
Cruz Biotech.). Pellets were washed twice with cold
phosphate-bu¡ered saline containing 1% NP-40 and
2 mM sodium vanadate. The pellets were washed
with 100 mM Tris, pH 7.5, 0.5 M LiCl and then
with reaction bu¡er containing 12.5 mM MOPS,
pH 7.5, 12.5 mM L-glycerophosphate, 7.5 mM
MgCl2, 0.5 mM EDTA, 0.5 mM NaF and 0.5 mM
sodium vanadate. The immunoprecipitates were re-
suspended in 30 Wl reaction bu¡er containing 1 WCi
[Q-32P]ATP, 20 WM ATP and 1 Wg GST-Jun (Upstate
Biotechnology) and incubated for 20 min at 30‡C.
The samples were resolved in a 12% SDS^acrylamide
gel. The phosphorylated products were visualized
and quantitated using a phosphorimager and Image-
Quant software (Molecular Dynamics).
3. Results
3.1. Altered growth factor and receptor expression in
drug resistant MCF-7 sublines
Twenty drug resistant human breast cancer sub-
lines were previously studied, and frequent upregula-
tion of growth factors and receptors was reported
[55]. Three sublines of MCF-7 were chosen for fur-
ther studies in order to ask whether the growth fac-
tor and receptor overexpression contributed to the
resistant phenotype. The resistant sublines, having
di¡erent resistance mechanisms, included two ob-
Table 1
Selection conditions, relative resistance and growth rate in drug resistant MCF-7 breast cancer sublines
Cell line Concentration of drug
selected ina :
MDR-1 unitsb Relative
resistancec
Relative resistance
with verapamilc
Doubling time (h)d
MCF-7 1 1 1 34.6
MCF-7 AdVpe 100 ng/ml Ad 1 181 224 58.1
MCF-7 Ad75 75 ng/ml Ad 15 29 10 77.3
MCF-7 Tx200 200 ng/ml PTX 40 323 246 27 79.3
aCells were stable for at least 6 months in the indicated amount of drug, but were cultured out of drug for 1 week prior to all experi-
ments.
bExpression of MDR-1 mRNA was measured by quantitative PCR.
cRelative resistance refers to the fold increase in IC50 of the drug resistant cell line compared to the IC50 of MCF-7 parental cells for
the selecting agent; the same experiment was also performed in the presence of 5 Wg/ml verapamil to inhibit P-glycoprotein.
d2000 cells/well were plated in 96 well plates and 3, 5 and 7 days later ¢xed (n = 4). The cells were stained and evaluated as described
in Section 2. An exponential growth curve was obtained from which doubling times were calculated.
eThe selecting agent for MCF-7 AdVp was adriamycin in the presence of 5 Wg/ml verapamil.
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tained by disparate adriamycin selections, and one
selected in paclitaxel. The expression of TGFK,
EGF and EGFR mRNA was con¢rmed by RNase
protection assay (Fig. 1). As shown, increases in
TGFK expression were observed in three of the sub-
lines. The expression increased between 4- and 72-
fold as determined by densitometry when normalized
to the 36B4 signal. The largest increase was observed
for MCF-7 Tx200 (72-fold). No change in EGF
mRNA expression could be detected in these sub-
lines. EGFR expression was increased in the MCF-
7 AdVp (63-fold) subline. The RNA results were
consistent in at least three separate experiments.
3.2. Characterization of drug resistant sublines
The growth rate and contribution of primary re-
sistance mechanisms was evaluated in the earlier
study [55]. The relative resistance is de¢ned as the
IC50 of the drug resistant subline divided by the
IC50 of MCF-7 parental cells for the selecting agent
(Table 1). Reversal of resistance by verapamil could
be detected in the Tx200 subline, consistent with
MDR-1/P-glycoprotein as a principal mechanism of
drug resistance. Expression of MDR-1 mRNA at
high levels was con¢rmed in this cell line, and was
also detectable in MCF-7 Ad75, using a quantitative
PCR technique. These levels can be compared to al-
most undetectable levels in parental MCF-7 cells.
Downregulation of topoisomerase IIK expression to
19% of wild type levels may be the primary mecha-
nism of resistance in the MCF-7 Ad75 cells. Recent
studies have shown resistance in MCF-7 AdVp cells
to be due to gene ampli¢cation and overexpression
of a novel half-transporter, MXR [34]. Upregulated
growth factor and receptor expression in the resistant
sublines could be expected to increase proliferative
activity. However, as shown in Table 1, all analyzed
drug resistant cell lines had a reduced growth rate
under normal culture conditions (in the presence of
10% FCS, and out of drug), with a 1.7^2.3-fold in-
crease in length of the doubling times of the sublines
when compared to the parental MCF-7 cells.
3.3. EGFR immunoblot and immunoprecipitation
Response of the EGFR to stimulation with EGF
was evaluated in whole cell lysates and by immuno-
precipitation. The receptor was di⁄cult to visualize
Fig. 2. Signal transduction pathways in drug resistant serum-
starved cells either untreated (3) or stimulated (+) with 1038 M
EGF for 5 min. (Top) Tyrosine phosphorylation of Shc in
MCF-7 parental and resistant cells was examined following im-
munoprecipitation with anti-Shc antibody by immunoblotting
with anti-phosphotyrosine antibody. Results shown are repre-
sentative of four separate experiments. Shc was equally ex-
pressed in MCF-7 parental and drug resistant sublines, as dem-
onstrated by a separate immunoblot (data not shown). (Middle)
EGF-induced molecular weight shift of Raf-1 kinase in MCF-7
parental and resistant sublines. Cells were lysed and 70 Wg pro-
tein extract was examined by immunoblotting with an anti-Raf-
1 antibody. Results shown are representative of three experi-
ments. (Bottom) EGF-induced molecular weight shift of MAPK
in MCF-7 parental and resistant sublines. Cells were lysed and
75 Wg protein extract was analyzed by immunoblotting with
anti-MAPK antibody. The results shown are representative of
three separate experiments.
Fig. 1. Expression of TGFK, EGF, EGFR mRNA in parental
and drug resistant sublines. Total RNA was isolated and 30 Wg
analyzed using an RNase protection assay. 32P-Labeled anti-
sense fragments from TGFK, EGF, EGFR and 36B4 (control)
mRNA were protected against RNase degradation by hybrid-
ization to total RNA. The protected bands were separated on a
6% polyacrylamide gel and visualized by autoradiography.
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by both methodologies in all cell lines. Using an anti-
phosphotyrosine antibody in whole cell lysates, an
increased signal at 170 kDa could be detected in
parental cells and in all sublines (data not shown).
The signal was barely detectable in serum-starved
MCF-7, MCF-7 Ad75 and in MCF-7 Tx100 cells,
and increased s 5-, 2.8- and s 5-fold, respectively,
in these cell lines. Although basal levels were higher
in the MCF-7 AdVp subline, an increase of 2.4-fold
could be detected following EGF stimulation. This
indicated a response to EGF, and may represent
phosphorylated EGFR with other members of the
ErbB family. These experiments con¢rmed that
EGF was able to induce signaling in all cell lines.
3.4. Altered EGF-induced downstream signaling in
drug resistant sublines
To determine whether the increased EGFR expres-
sion was accompanied by activation of the signaling
pathway cascade, we examined the Shc, Raf-1 and
MAPK phosphorylation following EGF stimulation
in serum-starved cells. Overall tyrosine phosphory-
lation was previously shown to be increased in the
MCF-7 AdVp subline [55]. Stimulation with EGF
resulted in increased tyrosine phosphorylation of
Shc in the MCF-7 parental cells, as determined by
immunoprecipitation of Shc and probing of the im-
munoblot with an anti-phosphotyrosine antibody
(Fig. 2, top). EGF induced a 4-fold or greater stim-
ulation of Shc tyrosine phosphorylation in the MCF-
7 parental and Ad75 cells, while the stimulation was
reduced to 50% in MCF-7 AdVp and Tx200 (2.0-
and 2.1-fold, respectively). These di¡erences in Shc
phosphorylation were consistent in at least four ex-
periments. The 46 and 66 kDa isoforms of Shc pro-
tein were also observed.
As shown in Fig. 2, middle, the phosphorylation
of Raf-1 kinase was detected by a decrease in the
mobility of Raf-1. After stimulation with EGF,
Raf-1 phosphorylation increased in MCF-7 parental,
AdVp and Ad75 sublines. In contrast, no increase in
the phosphorylation of Raf-1 was detected in Tx200
cells, suggesting that the EGFR signaling pathway is
perturbed upstream or at the level of Raf-1 in these
cells. Comparable results were obtained in three sep-
arate experiments, suggesting persistently abnormal
signaling in these cells.
EGF-induced phosphorylation and activation of
MAPK results in reduced mobility and a shift to a
higher molecular weight form (Fig. 2, bottom). EGF-
induced phosphorylation of MAPK was comparable
in MCF-7 parental and in Ad75 cells, with 44% and
48%, respectively, of total MAPK shifted to the high-
er molecular weight form of MAPK. Less phosphor-
ylated MAPK was detected in AdVp (12%), and es-
pecially in the Tx200 cells in which no higher
molecular weight band was observed when compared
to parental cells, suggesting that the growth factor
signaling pathway is fully inhibited upstream of
MAPK in these cells.
3.5. Decreased EGF-induced c-fos mRNA expression
in most drug resistant sublines
Activation of the EGFR signaling pathway even-
Table 2
Quantitation of EGF-induced events in the signaling pathway of parental and drug resistant MCF-7 cells
Cell line Shc tyrosine
phosphorylationa
Raf-1 phosphorylationb MAPK phosphorylation
in % of totalc
Relative c-fos mRNA
inductiond
MCF-7 1.0 + 1.0 1
MCF-7 AdVp 0.5 + 0.25 1.91
MCF-7 Ad75 1.5 + 1.1 0.31
MCF-7 Tx200 0.5 3 0 0.12
aThe values obtained by densitometry for the tyrosine-phosphorylated 52 kDa Shc protein in EGF-stimulated cells were divided by
the values of the non-stimulated cells and expressed relative to the level in the parental MCF-7 cells.
bPresence (+) or absence (3) of decreased Raf-1 mobility, indicative of EGF-induced phosphorylation.
cThe densitometric value of the higher molecular weight band of MAPK was divided by the sum of the two molecular weight bands
of MAPK when stimulated with EGF and expressed relative to the level in the parental MCF-7 cells.
dThe densitometric value of the EGF-induced c-fos signal in the drug resistant cells, normalized to the 36B4 control, was divided by
that for parental MCF-7 cells and expressed as ratio.
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tually leads to gene induction. Induction of c-fos
mRNA expression by EGF is well described and
has been demonstrated to precede growth stimula-
tion [9]. The induction of c-fos mRNA expression
by EGF was compared in MCF-7 parental and
drug resistant sublines (Fig. 3). EGF-induced c-fos
mRNA expression was reduced in Ad75 and Tx200
cells. The intensity of the c-fos mRNA signal was
0.31 and 0.12 compared to that in the MCF-7 paren-
tal cells when normalized to the 36B4 control, as
determined by densitometry. Despite reduced up-
stream components, c-fos induction was increased
in MCF-7 AdVp cells (1.91 compared to 1 for the
parental cells). Thus, signaling pathway perturba-
tions at various levels were found in drug resistant
sublines. Table 2 provides quantitation of the data
presented in Figs. 2 and 3. Almost no signaling could
be detected in the slowly growing Tx200 cells.
3.6. Normal anisomycin-induced SAPK activity in
drug resistant cells
The stress-activated protein kinase (SAPK), part
of a signal transduction cascade related to but dis-
tinct from the MAPK pathway, is activated in re-
sponse to a variety of cellular stresses [53]. Agonists
known to activate SAPK in vivo include anisomycin,
UV-light, TNFK and oncogenes [53]. SAPK activa-
tion leads to phosphorylation of the c-Jun activation
domain [14]. Having shown perturbations in the
EGFR signaling pathway, we asked whether the
stress-activated signaling pathway was altered in
drug resistant cells following continuous exposure
to cytotoxic compounds. SAPK activity was exam-
ined following anisomycin treatment. As shown in
the upper panel of Fig. 4, in both MCF-7 and the
drug resistant sublines, anisomycin treatment re-
sulted in reduced mobility of SAPK, re£ecting the
phosphorylated and activated state of the kinase.
We immunoprecipitated the SAPK and used it to
phosphorylate an N-terminal c-Jun construct (GST-
Jun). The lower panel of Fig. 4 shows that anisomy-
cin-induced SAPK activity is relatively equal in the
parental and the drug resistant sublines. Thus no
signi¢cant alterations in the level of SAPK were ob-
served in the drug resistant cells. These results were
reproduced in at least three experiments.
Fig. 4. Anisomycin-induced SAPK activity in parental and drug
resistant cells. Cells were untreated or treated with 1 Wg/ml ani-
somycin for 1 h. Cells were lysed and 30 Wg protein extracts
were examined by immunoblotting with an anti-SAPK antibody
(upper panel). The blot was reprobed with anti-actin antibody
to con¢rm regular loading (middle panel). 1 mg protein extract
was immunoprecipitated with anti-SAPK and assayed for GST-
Jun kinase activity. The reacted extracts were subjected to
SDS^PAGE and incorporated 32P was visualized by the phos-
phorimager. The phosphorylated GST-Jun band is indicated
(lower panel). The results shown are representative of three ex-
periments.
Fig. 3. EGF-stimulated c-fos mRNA induction in parental and
drug resistant MCF-7 cells. Serum-starved cells were incubated
without (3) or with (+) 1038 M EGF for 25 min. Cells were
lysed and RNA prepared with RNA-STAT as described in Sec-
tion 2. Total RNA (30 Wg) was analyzed using an RNase pro-
tection assay. 32P-Labeled antisense fragments from c-fos and
36B4 (control) mRNA were protected against RNase degrada-
tion by hybridization to total RNA. The protected bands were
separated on a 6% polyacrylamide gel and visualized by autora-
diography. The results shown are representative of three sepa-
rate experiments.
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3.7. Di¡erential e¡ect of reduced proliferative activity
on the sensitivity to cytotoxic agents in parental
and drug resistant cells
It has been repeatedly shown that actively prolif-
erating cells are more vulnerable to the e¡ects of
most anticancer drugs than quiescent cells
[1,17,28,33]. To determine the e¡ect of the altered
signaling pathway and the reduced growth rate on
drug sensitivity in these sublines, we examined the
e¡ect of reduced proliferative activity on cellular sen-
sitivity to cytotoxic compounds. As depicted in Fig.
5A, all cell lines were inhibited in their proliferative
activity by low serum conditions (0.2% FCS). As
shown in Fig. 5B,C, this reduction in growth rate
resulted in a marked increase in resistance to doxo-
rubicin or paclitaxel in the MCF-7 parental cells
whereas modest or no signi¢cant di¡erences in sensi-
tivity were observed for the drug resistant sublines.
The IC50 values in MCF-7 parental cells increased
from 7.4 to s 1000 ng/ml for doxorubicin and
from 1 to s 1000 ng/ml for paclitaxel. At most, in
the drug resistant sublines, IC50 values increased 10-
fold. These studies suggest that the endogenous
growth inhibition present in these sublines already
contributes maximally to their drug resistance.
Fig. 5. (A) Growth response study of the MCF-7 and drug resistant sublines in 0.2% (closed symbols) and 10% FCS (open symbols).
Between 1000 and 4000 cells/well were seeded in 96 well plates in quadruplicates. The cells were ¢xed on the indicated days and ana-
lyzed as described in Section 2. The increase in cell number is expressed as the ratio of the OD on the indicated days and the OD on
day 1. (B) Cytotoxicity analysis of MCF-7 parental and doxorubicin resistant sublines in 0.2% and 10% FCS. (C) Cytotoxicity analy-
sis of MCF-7 parental and MCF-7 Tx200 paclitaxel resistant subline in 0.2% and 10% FCS. Between 1000 and 8000 cells/well were
plated in 96 well plates. Cultures were preincubated in growth medium supplemented with 0.2% or 10% FCS for 24 h to permit recov-
ery from trypsinization and then incubated for an additional 4 days with growth medium alone or indicated drug in growth medium.
Data represent the mean value of quadruplicates.
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4. Discussion
Altered EGFR expression was previously observed
in multidrug resistant sublines, with increases and
decreases in receptor levels reported [15,42,51]. To
avoid the pitfalls associated with examination of a
single model system, we examined growth factor
and growth factor receptor expression in 15 drug
resistant human breast cancer sublines derived by
exposure to cytotoxic drugs [55]. Upregulation of
TGFK and EGFR was frequently observed, coupled
with a decreased growth rate. In the studies pre-
sented here, reproducible but di¡ering abnormalities
of the EGFR signaling pathway were identi¢ed in
three drug resistant sublines when compared to the
parental MCF-7 cells. Decreased proliferative activ-
ity resulted in a marked increase in resistance in
MCF-7 parental cells, con¢rming an e¡ect of prolif-
erative rate on drug resistance.
It should be noted at the outset that overexpres-
sion of drug transporters or downregulation of top-
oisomerase IIK is the major contributor to the drug
resistant phenotype in these cells. However, the ob-
served upregulation of growth factors and growth
factor receptors led us to hypothesize that growth
factor signaling pathways could also play a role in
the drug resistance observed. Evidence in clinical on-
cology has also suggested that growth factor path-
ways may play a role in drug resistance: tumors of
patients with elevated EGFR expression have a gen-
erally worse prognosis with shorter relapse-free sur-
vival and overall survival observed [11,37,45]. Simi-
larly, it has been reported that higher doses of
chemotherapy are required to achieve therapeutic
bene¢t in breast cancers overexpressing ErbB2
[21,36,52]. An in vitro model with EGFR-transfected
clones of the human breast cancer cell line ZR75B
supported a similar conclusion. These clones dis-
played a 2^6-fold increase in resistance to doxorubi-
cin, vinblastine, cisplatin and 5-£uorouracil relative
to the neomycin-transfected control clone [16]. In
addition, the EGFR in transfected cells conferred
a selective advantage to the cells during drug expo-
sure.
The importance of EGFR signaling in responsive-
ness to chemotherapy has also been substantiated by
studies combining chemotherapy with treatments tar-
geted to the EGFR, and by corollary studies with
ErbB2. Studies both in laboratory models and in
clinical trials have suggested that targeting the recep-
tors may improve responsiveness to chemotherapy.
Addition of C225 monoclonal antibody against the
EGFR sensitized epidermoid and breast cancer cells
to doxorubicin or cisplatin in xenograft models
[3,18]. Addition of the tyrosine kinase inhibitor
AG1478 has sensitized lung cancer cells to cisplatin
[29]. Addition of an antibody to ErbB2, rhuMAb
HER2 (herceptin), sensitizes breast cancer cells to
cisplatin and to taxol both in laboratory models
and in clinical trials [2,40,41]. The mechanism by
which these agents increase chemosensitivity is not
well understood but is not strictly due to interruption
of signaling. In our in vitro studies, the C225 mono-
clonal antibody against the EGFR cells did not con-
sistently sensitize the MCF-7 and MCF-7 AdVp cells
to doxorubicin (data not shown). Since the antibody
itself can cause growth inhibition, this could have
negated any cell sensitization that resulted from the
addition of C225.
One alternate hypothesis which could be consid-
ered is that the EGFR in these drug resistant cells
is signaling a survival pathway rather than a mito-
genic pathway. A role for EGF in promoting sur-
vival, rather than proliferation, of the normal mam-
mary epithelium has been suggested [12,31,43,48].
One likely mechanism is that the EGFR, in addition
to MAPK activation has been linked to Akt/protein
kinase B (PKB) by signaling through PI3 kinase
[7]. Activation of the Akt/PKB serine/threonine pro-
tein kinase has been shown to have an anti-apoptotic
e¡ect in several model systems [13,24]. Further-
more, crosstalk between Raf and Akt has been dem-
onstrated, with phosphorylation of Raf by Akt
[57]. If this connection was con¢rmed, then treat-
ments targeting EGFR may interfere with survival
signals.
From the point of view of EGF-induced mitogen-
esis, the upregulation of growth factor and receptor
expression in the drug resistant sublines is apparently
inconsistent with the observed reduced growth rate.
Most studies in clinical samples have suggested that
EGFR or ErbB2 overexpression correlate positively
with Ki67 or other markers of proliferation [8,22,39].
To explain this contradiction, we examined the
EGFR signaling pathway in three sublines, in com-
parison to the MCF-7 parental cells. We found the
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pathway to be abnormal in each of the sublines,
although at di¡erent levels. The observed perturba-
tions were sometimes small but quite reproducible.
In one case, portions of the pathway were downreg-
ulated, but downstream components recovered to
normal or higher levels following EGF stimulation.
However, this did not lead to normal signaling since
the net e¡ect, lower growth rate, is observed in all
the sublines.
Upregulated EGFR without concomitant mitogen-
ic activity has been previously observed in at least
two model systems [19,35]. MDA-MB-468 and A431
have high levels of EGFR, but are growth-inhibited
following treatment with 1038 M EGF. Indeed, re-
cent studies have shown that senescence mediated by
p53 and p16 occurs in response to excess mitogenic
signaling in normal rodent ¢broblasts [30].
Examination of the signal transduction pathway
in the drug resistant sublines revealed distinctive
and di¡erent alterations. In the most straightforward
example, MCF-7 Tx200, inhibition of all the exam-
ined steps in the EGFR signaling cascade was ob-
served. The observed reduction in growth rate in
these cells can be easily linked to the inhibited signal
transduction. However, in the remaining sublines,
the results are less straightforward. In the MCF-7
AdVp subline, the signaling pathway is inhibited at
the level of Shc and persists at the level of MAPK.
The MCF-7 Ad75 cells appeared to have normal
signal transduction at every level examined except
c-fos mRNA induction, which was 31% of parental
levels.
Thus, our studies have shown a paradoxical upreg-
ulation of growth factor and receptor, impaired sig-
naling and reduced growth rate in drug resistant
cells. It is well established that actively proliferating
cells are more vulnerable to the e¡ects of most anti-
cancer drugs than are quiescent cells [1,17,28,33]. In
fact, treatment of cells with EGF has been shown to
increase sensitivity to platinum and paclitaxel [26].
All the examined drug resistant breast cancer cells
demonstrated a decreased growth rate. The doubling
time increased in the resistant sublines from 1.7- to
2.3-fold over that observed in the MCF-7 parental
cells. We con¢rmed that decreased proliferative ac-
tivity due to serum starvation resulted in a marked
increase in resistance to doxorubicin and paclitaxel
in the MCF-7 parental cells. Interestingly, reduced
proliferative activity due to serum starvation had
less e¡ect on the sensitivity to cytotoxic agents in
the resistant sublines, possibly because the underly-
ing reduction in growth rate already contributed
maximally to their resistant phenotype. Reduced
growth rate may confer resistance by allowing cells
time to repair damage to drug targets, much as has
been postulated for p53 induction. Furthermore, re-
duced growth rate can be viewed as being a mecha-
nism of resistance that cells may have ready access
to which, while not conferring high levels of resis-
tance like MDR-1 overexpression, may allow the de-
velopment of more e⁄cient drug resistance mecha-
nisms.
It is our hypothesis that the perturbed EGFR sig-
naling pathway mediates the reduced growth rate
observed in the drug resistant cells and contributes
to the onset or maintenance of the drug resistant
phenotype. This aberrant signaling occurs in re-
sponse to chronic drug exposure and selection for
drug resistance. Since recent studies have shown
that overexpression of mitogenic pathways provokes
upregulation of cell cycle inhibitors including p14-
ARF (human homologue of p16) [30], the upregu-
lated growth factor receptor may in fact promote
the slower growth rate. In the clinical setting, studies
are needed to examine the prevention or reversal of
drug resistance with compounds that target the
EGFR.
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